Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson's Disease: A Multicenter Study.
123I-FP-CIT
123I-MIBG
Parkinson’s disease
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
07
07
2023
revised:
10
08
2023
accepted:
19
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Parkinson's disease is a progressive neurodegenerative disorder, with incidence and prevalence rates of 8-18 per 100,000 people per year and 0.3-1%, respectively. As parkinsonian symptoms do not appear until approximately 50-60% of the nigral DA-releasing neurons have been lost, the impact of routine structural imaging findings is minimal at early stages, making Parkinson's disease an ideal condition for the application of functional imaging techniques. The aim of this multicenter study is to assess whether 123I-FP-CIT (DAT-SPECT), 123I-MIBG (mIBG-scintigraphy) or an association of both exams presents the highest diagnostic accuracy in de novo PD patients. 288 consecutive patients with suspected diagnoses of Parkinson's disease or non- Parkinson's disease syndromes were analyzed in the present Italian multicenter retrospective study. All subjects were de novo, drug-naive patients and met the inclusion criteria of having undergone both DAT-SPECT and mIBG-scintigraphy within one month of each other. The univariate analysis including age and both mIBG-SPECT and DAT-SPECT parameters showed that the only significant values for predicting Parkinson's disease in our population were eH/M, lH/M, ESS and LSS obtained from mIBG-scintigraphy ( mIBG-scintigraphy shows higher diagnostic accuracy in de novo Parkinson's disease patients than DAT-SPECT, so given the superiority of the MIBG study, the combined use of both exams does not appear to be mandatory in the early phase of Parkinson's disease.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease is a progressive neurodegenerative disorder, with incidence and prevalence rates of 8-18 per 100,000 people per year and 0.3-1%, respectively. As parkinsonian symptoms do not appear until approximately 50-60% of the nigral DA-releasing neurons have been lost, the impact of routine structural imaging findings is minimal at early stages, making Parkinson's disease an ideal condition for the application of functional imaging techniques. The aim of this multicenter study is to assess whether 123I-FP-CIT (DAT-SPECT), 123I-MIBG (mIBG-scintigraphy) or an association of both exams presents the highest diagnostic accuracy in de novo PD patients.
METHODS
METHODS
288 consecutive patients with suspected diagnoses of Parkinson's disease or non- Parkinson's disease syndromes were analyzed in the present Italian multicenter retrospective study. All subjects were de novo, drug-naive patients and met the inclusion criteria of having undergone both DAT-SPECT and mIBG-scintigraphy within one month of each other.
RESULTS
RESULTS
The univariate analysis including age and both mIBG-SPECT and DAT-SPECT parameters showed that the only significant values for predicting Parkinson's disease in our population were eH/M, lH/M, ESS and LSS obtained from mIBG-scintigraphy (
CONCLUSIONS
CONCLUSIONS
mIBG-scintigraphy shows higher diagnostic accuracy in de novo Parkinson's disease patients than DAT-SPECT, so given the superiority of the MIBG study, the combined use of both exams does not appear to be mandatory in the early phase of Parkinson's disease.
Identifiants
pubmed: 37629643
pii: life13081786
doi: 10.3390/life13081786
pmc: PMC10455638
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Neurol Sci. 2018 Feb 15;385:17-21
pubmed: 29406901
Int Rev Neurobiol. 2017;133:179-257
pubmed: 28802921
Int Rev Neurobiol. 2019;149:137-192
pubmed: 31779811
J Neuropathol Exp Neurol. 1993 May;52(3):183-91
pubmed: 7684074
Nat Rev Dis Primers. 2022 Aug 25;8(1):56
pubmed: 36008429
Curr Radiopharm. 2020;13(2):120-129
pubmed: 31985388
Aust N Z J Psychiatry. 2019 Apr;53(4):291-303
pubmed: 30848660
Parkinsonism Relat Disord. 2012 Jun;18(5):494-500
pubmed: 22321865
Neuroscience. 2012 Jan 27;202:424-33
pubmed: 22138505
J Nucl Cardiol. 2019 Aug;26(4):1188-1196
pubmed: 29594915
Curr Alzheimer Res. 2021;18(3):196-207
pubmed: 34102975
J Nucl Med. 2000 Jan;41(1):71-7
pubmed: 10647607
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Parkinsonism Relat Disord. 2015 May;21(5):489-93
pubmed: 25753457
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Parkinsonism Relat Disord. 2020 May;74:67-73
pubmed: 32536421
Clin Auton Res. 2012 Feb;22(1):43-55
pubmed: 21792729
Parkinsonism Relat Disord. 2014 Mar;20(3):267-73
pubmed: 24332912
Mol Imaging Biol. 2020 Jun;22(3):703-710
pubmed: 31309370
Medicine (Baltimore). 2017 May;96(21):e6967
pubmed: 28538394
Synapse. 1997 Nov;27(3):183-90
pubmed: 9329154
Parkinsonism Relat Disord. 2018 Apr;49:95-99
pubmed: 29336906
N Engl J Med. 2003 Apr 3;348(14):1356-64
pubmed: 12672864
Neurol Clin. 1996 May;14(2):317-35
pubmed: 8827174
Neurodegener Dis. 2010;7(5):341-7
pubmed: 20616568
Front Pharmacol. 2020 Apr 08;11:435
pubmed: 32322208
Diagnostics (Basel). 2022 Oct 07;12(10):
pubmed: 36292111
Mov Disord Clin Pract. 2018 Nov 09;6(1):46-50
pubmed: 30746415
Clin Med (Lond). 2016 Aug;16(4):371-5
pubmed: 27481384
Curr Radiopharm. 2021;14(1):64-69
pubmed: 32720610
Pract Neurol. 2021 Oct;21(5):376-383
pubmed: 34215700
Diagnostics (Basel). 2022 Feb 02;12(2):
pubmed: 35204476
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):435-63
pubmed: 27042903
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):314-9
pubmed: 9527140
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Q J Nucl Med. 2001 Jun;45(2):139-52
pubmed: 11476163
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):434-42
pubmed: 19838704
J Neurochem. 2016 Oct;139 Suppl 1:318-324
pubmed: 27401947
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2146-53
pubmed: 20567820
Mov Disord. 2011 Jun;26(7):1218-24
pubmed: 21480373
Front Neurol. 2020 Mar 10;11:180
pubmed: 32218768
J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105
pubmed: 8558176